EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Radiosynthesis and Preclinical Evaluation of Enantiopure ( R )‑[18F]Fluorolactate for PET Imaging of Metabolic Processes

Xiaoqing Zhuang, Jenni Virta, Negar A Samani iD, Tomi T Airenne, Maxwell W G Miner, Heidi Liljenbäck iD, Aino Latva-Rasku, Mitra Gerami, Jesse Ponkamo, Nea Läpinen, Pyry Dillemuth, Johan Rajander iD und 5 weitere

Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5305-5317

DOI: 10.1021/acs.molpharmaceut.6c00236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 25.07.2026. Verfasst von Xiaoqing Zhuang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Turku PET Centre, University of Turku, FI-20520Turku, Finland. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Positron-Emission Tomography, Fluorine Radioisotopes, Lactic Acid. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Finland, Terveyden Tutkimuksen Toimikunta, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

L-Lactate is a key substrate in energy metabolism and a potential biomarker for cancer and metabolic disorders. We developed an enantiomerically pure positron emission tomography (PET) tracer, (R)-[18F]fluorolactate, to mimic natural L-lactate. (R)-[18F]Fluorolactate was synthesized via nucleophilic ring-opening of benzyl (S)-oxirane-2-carboxylate, optimized to yield >91% radiochemical purity, > 95% enantiomeric excess, pH 6, and >5.56 GBq/μmol molar activity. PET/computed tomography (CT) imaging, biodistribution, autoradiography, and stability analyses were conducted in fasted and nonfasted rats and in mice bearing subcutaneous Lewis lung carcinoma (LLC) tumors. In rats, tracer uptake was highest in the kidneys and liver, with fasting further increasing renal and hepatic uptake. In mice, (R)-[18F]fluorolactate accumulated in tumors. The monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 significantly reduced tracer uptake in normal tissues and LLC tumors, and increased renal excretion, confirming MCT1-mediated transport. More than 80% and 90% of the tracer remained intact in plasma at 70 min postinjection in rats and tumor-bearing mice, respectively. In silico structural analyses supported the experimental findings. (R)-[18F]Fluorolactate is a metabolically stable, MCT1-sensitive PET tracer suitable for noninvasive assessment of lactate transport and metabolism and shows promise for imaging MCT1-dependent lactate transport in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsPositron-Emission TomographyFluorine RadioisotopesLactic AcidAnimalsRatsMiceTissue DistributionMaleCarcinoma, Lewis LungMonocarboxylic Acid TransportersPositron Emission Tomography Computed TomographySymportersMonocarboxylate Transport Protein 1Mice, Inbred C57BLStereoisomerismQuinazolinesPyrimidinonesThiophenes

Stichwörter der Autor:innen

cancerenergy metabolismintermediatemetabolic disorderspositron emission tomography

Substanzen

RadiopharmaceuticalsAZD3965Fluorine RadioisotopesMonocarboxylic Acid TransportersLactic AcidSymportersMonocarboxylate Transport Protein 1QuinazolinesPyrimidinonesThiophenes

Autor:innen und Institutionen

  • Turku PET Centre, University of Turku, FI-20520Turku, Finland.
  • Department of Chemistry, University of Turku, FI-20500Turku, Finland.
  • Structural Bioinformatics Laboratory and InFLAMES Research Flagship Center, Biochemistry, Department of Natural and Health Sciences, Åbo Akademi University, FI-20520Turku, Finland.
  • Turku PET Centre, Turku University Hospital, FI-20520Turku, Finland.
  • Accelerator Laboratory, Åbo Akademi University, FI-20520Turku, Finland.
  • Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, SE-40530Göteborg, Sweden.

ORCID-Profile: Negar A Samani, Heidi Liljenbäck, Johan Rajander, Tiina A Salminen, Xiang-Guo Li, Anne Roivainen

Förderung

  • Research Council of Finland
  • Terveyden Tutkimuksen Toimikunta
  • Novo Nordisk Fonden
  • Wellbeing Services County of Southwest Finland
  • Profi 7-ImmunoCAP

Zitieren

APA

Zhuang, X., Virta, J., Samani, N. A., Airenne, T. T., Miner, M. W. G., Liljenbäck, H., Latva-Rasku, A., Gerami, M., Ponkamo, J., Läpinen, N., Dillemuth, P., Rajander, J., Salminen, T. A., Enerbäck, S., Nuutila, P., Li, X. G., & Roivainen, A. (2026). Radiosynthesis and Preclinical Evaluation of Enantiopure ( R )‑[18F]Fluorolactate for PET Imaging of Metabolic Processes. Molecular Pharmaceutics, 23(11), 5305-5317. https://doi.org/10.1021/acs.molpharmaceut.6c00236

Vancouver

Zhuang X, Virta J, Samani NA, Airenne TT, Miner MWG, Liljenbäck H, et al. Radiosynthesis and Preclinical Evaluation of Enantiopure ( R )‑[18F]Fluorolactate for PET Imaging of Metabolic Processes. Molecular Pharmaceutics. 2026;23(11):5305-5317. doi:10.1021/acs.molpharmaceut.6c00236

BibTeX
@article{Zhuang2026,
  author = {Zhuang, Xiaoqing and Virta, Jenni and Samani, Negar A and Airenne, Tomi T and Miner, Maxwell W G and Liljenbäck, Heidi and Latva-Rasku, Aino and Gerami, Mitra and Ponkamo, Jesse and Läpinen, Nea and Dillemuth, Pyry and Rajander, Johan and Salminen, Tiina A and Enerbäck, Sven and Nuutila, Pirjo and Li, Xiang-Guo and Roivainen, Anne},
  title = {Radiosynthesis and Preclinical Evaluation of Enantiopure ( R )‑[18F]Fluorolactate for PET Imaging of Metabolic Processes},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {11},
  pages = {5305--5317},
  doi = {10.1021/acs.molpharmaceut.6c00236}
}
Kostenlos starten →